{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:51:15Z","timestamp":1772491875132,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clml.2016.02.029","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T10:08:49Z","timestamp":1470737329000},"page":"S114-S123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S","title":["How to Treat Essential Thrombocythemia and Polycythemia Vera"],"prefix":"10.1016","volume":"16","author":[{"given":"Carlos","family":"Besses","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.029_bib1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-tern survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib2","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib4","article-title":"Management of polycythemia vera: a critical review of current data","author":"McMullin","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjh.13605","article-title":"How we diagnose and treat essential thrombocythemia","volume":"171","author":"Alimam","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2016.02.029_bib7","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib10","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2007-996119","article-title":"Acquired von Willebrand disease in patients with high platelet counts","volume":"23","author":"Budde","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2016.02.029_bib13","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.029_bib14","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden score system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib15","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2014-05-577635","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"124","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.029_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-014-0226-1","article-title":"Antiplatelet therapy in the management of myeloproliferative neoplasms","volume":"9","author":"Alvarez-Larran","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2016.02.029_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bjh.12321","article-title":"Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythemia: an observational study","volume":"161","author":"Alvarez-Larran","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1602.1602","article-title":"A\u00a0study of the role of antiplatelet therapy in the prevention of thrombosis in patients with CALR-mutated low-risk essential thrombocythemia","volume":"126","author":"Alvarez-Larran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","article-title":"Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia","volume":"94","author":"Hernandez-Boluda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.029_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12032-009-9180-5","article-title":"High prevalence of restless legs syndrome among patients with polycythemia vera treated with venesection","volume":"27","author":"Tobiasson","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3411 patients with Ph-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4065\/73.10.961","article-title":"Multiple skin cancers associated with hydroxyurea therapy","volume":"73","author":"Best","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2016.02.029_bib26","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.029_bib28","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib29","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib30","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","author":"Kiladjian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.029_bib31","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib32","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib33","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interfer\u00f3n therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.60.60","article-title":"Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia and polycythemia vera: results after a median 7-year follow-up phase 2 study","volume":"126","author":"Masarova","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib35","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induced high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.23928","article-title":"Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b","volume":"90","author":"Them","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib37","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kiladjian","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.029_bib39","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.029_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.029_bib41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2016.02.029_bib42","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib43","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.leukres.2011.07.031","article-title":"Anagrelide and cardiovascular events: much ado about nothing?","volume":"35","author":"Besses","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2016.02.029_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.leukres.2012.11.004","article-title":"Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study","volume":"37","author":"Besses","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2016.02.029_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ejh.12381","article-title":"Target hematologic values in the management of essential thrombocythemia and polycythemia vera","volume":"94","author":"Hernandez-Boluda","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08122.x","article-title":"Guidelines for investigation and management of adults and children presenting with a thrombocytosis","volume":"149","author":"Harrison","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib47","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib48","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib49","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT-1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythemia","volume":"152","author":"Hernandez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A\u00a0unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.029_bib52","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00277-014-2152-7","article-title":"Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea","volume":"93","author":"Alvarez-Larran","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib53","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larran","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A\u00a0unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib55","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythemia vera","volume":"172","author":"Alvarez-Larran","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.02.029_bib56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A\u00a0phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.02.029_bib57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.02.029_bib58","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib59","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Hernandez-Boluda","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.029_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOH.0000000000000017","article-title":"Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasms","volume":"21","author":"Rampal","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib61","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.029_bib62","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent in patients with high-risk primary myelofibrosis and myeloproliferative neoplasms in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2016.02.029_bib63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.hoc.2011.01.008","article-title":"Myeloproliferative disorders in pregnancy","volume":"25","author":"Harrison","year":"2011","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.clml.2016.02.029_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3324\/haematol.2015.131458","article-title":"Impact on mutational status on pregnancy outcome in patients with essential thrombocythemia","volume":"100","author":"Rumi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.029_bib65","article-title":"Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting","author":"Lishner","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.029_bib66","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.029_bib67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2007-07-102665","article-title":"Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey","volume":"111","author":"Ruggeri","year":"2008","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:34Z","timestamp":1761870514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":67,"alternative-id":["S2152265016000847"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.029","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Treat Essential Thrombocythemia and Polycythemia Vera","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}